Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial.

Circulation · 2023 · PMC10212585 · PMID 37070436

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Quality of life, assessed by Kansas City Cardiomyopathy Questionnaire, showed a trend toward greater improvements with empagliflozin (mean change in overall summary score, 9.81±1.27) compared with placebo (4.24±1.39).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.